Aripiprazole Tablet
Product Images NDC 43598-734

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 43598-734). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1.jpg (Aripiprazole Figure1)

A forest plot titled 'Effect of Other Drugs on Aripiprazole' displaying fold change and 90% confidence intervals in pharmacokinetic parameters AUC and Cmax of aripiprazole with various interacting drugs. The x-axis shows change relative to reference (without interacting drug), ranging from 0 to 3. Drugs include CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and others like valproate, lithium, and lorazepam.*

FDA Label Image

Figure-2.jpg (Aripiprazole Figure2)

A pharmacokinetic chart illustrating the effect of various drugs on Aripiprazole, showing changes in AUC and Cmax levels relative to a reference without interacting drugs. The chart compares CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam) with fold change and 90% confidence intervals on the x-axis from 0.5 to 3.*

FDA Label Image

Figure-3.jpg (Aripiprazole Figure3)

A chart titled 'Effect of Aripiprazole on Other Drugs,' showing fold change and 90% confidence intervals for various drugs' pharmacokinetic parameters (AUC, Cmax) relative to a reference without interacting drug. Drugs listed include dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine (including desmethylvenlafaxine), and escitalopram, with changes depicted on a horizontal axis from 0.5 to 3-fold.*

FDA Label Image

Figure-4.jpg (Aripiprazole Figure4)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' comparing AUC and Cmax values for special populations such as CYP2D6 metabolizers, gender, age groups, hepatic impairment, and severe renal impairment. The x-axis shows 'Change Relative to Reference' from 0.5 to 3.0, with data points and 90% confidence intervals represented as black squares with horizontal error bars.*

FDA Label Image

Figure-5.jpg (Aripiprazole Figure5)

A forest plot showing the fold change and 90% confidence intervals for dehydro-aripiprazole pharmacokinetics parameters AUC and Cmax. Variables compared include CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment with change relative to reference values on the x-axis.*

FDA Label Image

Figure-6.jpg (Aripiprazole Figure6)

A Kaplan-Meier plot showing the proportion of subjects with relapse over time in days from randomization comparing Aripiprazole orally disintegrating tablets to placebo. The graph includes subject count at risk for both groups at multiple time points up to 182 days, illustrating a lower relapse proportion for Aripiprazole than placebo over the study period.*

FDA Label Image

Figure 7 (Aripiprazole Figure7)

A line graph comparing the proportion of subjects with relapse over days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization (0 to 182), and the y-axis shows the proportion with relapse (0.0 to 1.0). Numbers of subjects at risk for each group appear below the x-axis.*

FDA Label Image

Figure 8 (Aripiprazole Figure8)

A Kaplan-Meier survival curve chart comparing the proportion of relapse over 364 days between Aripiprazole and placebo groups in a clinical study. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. The chart includes the number of subjects at risk for each group sampled at various time points.*

FDA Label Image

10mg-30 (Aripiprazole Label1)

Aripiprazole Orally Disintegrating Tablets USP 10 mg oral tablet label from Dr. Reddy's Laboratories Inc. The label states each tablet contains 10 mg aripiprazole and includes pharmacist dispensing instructions. The package count is 30 tablets with storage and handling directions, manufacturer details, and a barcode also visible.*

FDA Label Image

15mg-30 (Aripiprazole Label2)

Label for Aripiprazole Orally Disintegrating Tablets, USP 15 mg by Dr. Reddy's Laboratories Inc. The label indicates a package of 30 tablets with prescription only status. It includes instructions for pharmacists to dispense the enclosed Medication Guide and storage conditions at controlled room temperature.*

FDA Label Image

Structural Formula (Aripiprazole Structure)

Chemical structure of Aripiprazole, shown as a molecular diagram with labeled chlorine atoms and ring systems, reflecting the active ingredient in Aripiprazole orally disintegrating tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.